News

Following recent observations of a sustained rise in rates of infections of Respiratory Syncytial Virus (RSV), it has been recommended that the palivizumab passive immunisation programme recommences.

Earlier this week, a new COVID-19 treatment became available across the UK for non-hospitalised children and young people aged 12 and over at the highest risk of severe COVID-19.

As RCPCH celebrates its 25th birthday, 25 members have shared stories about a case that stayed with them. These stories will be published throughout 2021.

As RCPCH celebrates its 25th birthday, 25 members have shared stories about a case that stayed with them. These stories will be published throughout 2021.

The Neonatal and Paediatric Pharmacist Group (NPPG), with support from the Royal College of Paediatrics of Child Health (RCPCH) has produced a proposal for a national approach for standardised intravenous infusion concentrations in children.

Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019 due to the presence of low levels of an impurity called NDMA. The European Medicines Agency has since confirmed its recommendation to suspend all ranitidine medicines in the EU.

Erythromycin in babies and infants has been associated with an increased risk of infantile hypertrophic pyloric stenosis.

Experts from 13 national bodies, including seven Royal Colleges, have joined forces to launch new practical guidance to support doctors and other health professionals around valproate use in women and girls in their reproductive years.

This guidance, updated in December 2020 and endorsed by RCPCH, has been produced to inform all healthcare professionals of best practice around the use and prescribing of valproate. It supports them to navigate situations that could arise as a result of prescribing valproate to women during childbea...

Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the World Health Organization (WHO) has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease.